Pfizer Reports Phase 2 MagnetisMM-3 Results for Elrexfio in Multiple Myeloma

Pfizer today announced results from the Phase 2 MagnetisMM-3 trial evaluating Elrexfio (elranatamab-bcmm) in patients with relapsed or refractory multiple myeloma who had received at least four prior lines of therapy. The trial demonstrated an overall response rate of 61%, with a complete response rate of 35% in heavily pretreated patients. These results led to FDA accelerated approval of Elrexfio.